Toyama, Japan

Makoto Takata


Average Co-Inventor Count = 8.9

ph-index = 2

Forward Citations = 35(Granted Patents)


Location History:

  • Toyama, JP (1990)
  • Toda, JP (1996)

Company Filing History:


Years Active: 1990-1996

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Makoto Takata: Innovator in Cerebrovascular Disease Treatment

Introduction

Makoto Takata is a prominent inventor based in Toyama, Japan. He has made significant contributions to the field of medicine, particularly in the development of compounds aimed at treating cerebrovascular diseases. With a total of 2 patents, his work has garnered attention for its potential impact on healthcare.

Latest Patents

Takata's latest patents include innovative compounds such as a 1,2-benzoisoxazole derivative or its salt, and a brain-protecting agent, specifically a piperazine derivative or its salt. These inventions are designed to address cerebrovascular diseases and improve recovery post-cerebrovascular incidents. One of his notable piperazine derivatives is represented by a specific formula, which is useful for curing cerebrovascular disease and post-cerebrovascular disease.

Career Highlights

Throughout his career, Takata has been associated with Toyama Chemical Co., Ltd., where he has been able to leverage his expertise in medicinal chemistry. His work has not only advanced scientific understanding but has also contributed to the development of practical solutions for serious health issues.

Collaborations

Takata has collaborated with notable colleagues such as Kenji Takeda and Joji Nakano, enhancing the research and development efforts within his field. Their combined expertise has fostered a productive environment for innovation.

Conclusion

In summary, Makoto Takata is a dedicated inventor whose work in developing treatments for cerebrovascular diseases is noteworthy. His contributions through patents and collaborations continue to influence the medical field positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…